A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

ClinicalTrials.gov ID: NCT00002423

Public ClinicalTrials.gov record NCT00002423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open-Label Trial for Treatment of HIV Infection in Subjects Who Have Failed Initial Combination Therapy With Regimens Containing Indinavir or Nelfinavir: Combination Therapy With 3TC (150 Mg BID), Abacavir (300 Mg BID) and Amprenavir (1200 Mg BID) Plus Either Nelfinavir (1250 Mg BID) or Indinavir (800 Mg TID) for 48 Weeks

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will compare the safety and effectiveness of two anti-HIV drug combinations in fighting HIV infection in patients whose viral loads (levels of HIV in the blood) rose with other anti-HIV drug treatments.

Study identification

NCT ID: NCT00002423
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Glaxo Wellcome; Industry
Enrollment: 100 participants

Conditions and interventions

Conditions

HIV Infections

Interventions

Drug

Eligibility (public fields only)

Age range: 13 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 1999
Primary completion: Not listed
Completion: Not listed
Last update posted: Jun 23, 2005

Started 1999

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Saint Francis Mem Hosp	San Francisco	California	94109	—
Georgetown Univ Med Ctr	Washington D.C.	District of Columbia	20007	—
IDC Research Initiative	Altamonte Springs	Florida	32701	—
Natl Institute of Allergy and Infectious Diseases	Bethesda	Maryland	20892	—
Kansas City AIDS Research Consortium	Kansas City	Missouri	64111	—
Bentley-Salick Med Practice	New York	New York	10011	—
Associates in Med and Mental Health	Tulsa	Oklahoma	74114	—
Portland Veterans Adm Med Ctr / Rsch & Education Grp	Portland	Oregon	972109951	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00002423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 23, 2005 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002423 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →